| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2017: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2016: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Outline of Final Research Achievements |
OLFM4 is a specific biomarker of inflammatory bowel disease(IBD). Its expression is induced biphasically. Aim of this study is clarifying the tumorigenesis mechanism of IBD by analyzing the induction of OLFM4.
OLFM4 was induced by NF-kappaB in ulcerative colitis(UC) and by AP-1(c-Jun/c-Fos) in Crohn disease(CD), independently. Its expression was correlated to the histological activity of UC and CD, respectively. Co-expression of OLFM4 and phospho-NF-kappaB/-65 was related to UC specifically, and suggested to be useful to differential diagnosis of UC and CD.
OLFM4 is a glycoprotein and binds Frizzled-7, a receptor of WNT pathway. It inhibits WNT pathway and epithelial mesenchymal transition. High expression of inflammatory foci of UC and reduction in associated tumor suggest OLFM4 might be a key molecule for the character of UC-associated tumor with high invasiveness and poor prognosis.
|
